Ace BioSciences and Crucell enter research and licensing agreement  

2005.11.07
Denmark's Ace BioSciences and Holland's Crucell have entered a research and licensing agreement to discover antibody therapies to combat serious iatrogenic infections

Denmark's Ace BioSciences and Holland's Crucell have entered a research and licensing agreement to discover antibody therapies to combat serious iatrogenic infections including those caused by antibiotic-resistant bacteria. Under the terms of the agreement, Crucell gains exclusive rights to assay a number of proprietary protein targets which Ace BioSciences has isolated and extracted from the cell surface of bacteria.

Ace BioSciences is ensured royalty and milestone payments on any therapies derived from the collaboration. Further financial details of the agreement have not been disclosed. The Danish company has recently gained further operating capital from investors including the Danish Fund for Industrial Growth, Dansk Innovationsinvestering and BankInvest.

Funen based Ace Biosciences was established in 2001, and specialises in developing novel protein-based vaccines and antibodies to infectious diseases. The company's first product currently under development is a vaccine to combat Campylobacter jejuni, the bacterium responsible for travellers' diarrhoea. The product is expected to enter clinical trials in 2006. The news was reported by regional newspaper Fyens Stiftstidende.

Link > Ace Biosciences 

Link > Crucell 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×